$CNXC

Concentrix Corp

No enriched coverage for $CNXC in the last 7 days.

No SEC Form 4 filings for $CNXC in the last 30 days.

Med

Groupe Bruxelles Lambert (CNXC) affiliates unload 6M Concentrix shares, keep 2.77M

Affiliates of Groupe Bruxelles Lambert, including FINPAR VI SA, FINPAR V SA, and Sapiens S.a r.l., executed an open-market sale of 6,000,000 shares of Concentrix Corp (CNXC) common stock at $22.25 per share on April 29, 2026. Following this significant transaction valued at $133.5 million, the reporting entities collectively retain indirect ownership of 2,773,667 Concentrix shares. This sale substantially reduces their holdings but leaves a notable remaining stake, with the filing indicating a "Very Negative" sentiment due to the large insider disposition.

These Analysts Cut Their Forecasts On Concentrix Following Q1 Results

Following its Q1 results, which showed mixed financial performance, Concentrix (NASDAQ: CNXC) has seen several analysts cut their price targets. Despite revenue slightly beating estimates, adjusted EPS missed, and the company issued Q2 guidance below expectations, leading to a 6.9% drop in its share price. Analysts from Baird, Canaccord Genuity, and Barrington Research maintained their ratings but significantly lowered their price targets for Concentrix.

Concentrix's (CNXC) Outperform Rating Reaffirmed at Barrington Research

Barrington Research has reaffirmed an "Outperform" rating for Concentrix (CNXC) with a $62 price target, indicating a potential 40.7% upside. This aligns with a "Moderate Buy" consensus from analysts, who have an average target of $66.25. The article also highlights recent insider buying by CEO Christopher Caldwell and significant institutional ownership in the company.

News on $CNXC